Atmofizer Techno - ATMFF STOCK NEWS

Atmofizer Technologies Inc. announced that its common shares will undergo a consolidation, effective January 12, 2023. The consolidation will result in one post-consolidated share for every twenty pre-consolidated shares, totaling approximately 6,687,390 shares outstanding. Shareholders will receive instructions on exchanging their shares via a letter from Odyssey Trust Company. Atmofizer focuses on air purification technology that neutralizes ultrafine particles and aims to enhance air quality and efficiency in various applications.

Atmofizer Technologies Inc. announced a 20:1 share consolidation of its common shares, reducing the total from 133,747,806 to approximately 6,687,390 shares. This decision, approved by the board of directors, does not require shareholder approval as per the Business Corporations Act of British Columbia. The consolidation aims to enhance stock performance and reduce operational costs in the air treatment industry, utilizing ultrafine particle agglomeration technology to improve air purification efficiency.

Atmofizer Technologies Inc. (OTCQB: ATMFF) reported significant progress in its HVAC technology development and financial results for Q3 2022. Revenue reached $210,000, a decline from $76,585 the previous year, alongside a gross profit of $60,293 (28.71%). The net loss widened to $16.1 million versus $5.9 million in 2021, driven mainly by high share-based payments. The company secured a crucial US patent for its agglomeration technology, enhancing its market position. Future growth is anticipated through partnerships in the HVAC sector, with product availability expected in early 2023.

On September 13, 2022, Atmofizer Technologies Inc. (CSE: ATMO) granted 6,600,000 restricted share units (RSUs) and 1,000,000 stock options to its directors and officers as part of its incentive plan. RSUs will vest at 1,650,000 units every three months for one year. The company focuses on innovative air purification technology to effectively manage harmful nano-scale particles. With a unique ultrasonic acoustic wave process, Atmofizer aims to enhance air safety and reduce operational costs in the air treatment industry.

Atmofizer Technologies Inc. (CSE: ATMO, OTCQB: ATMFF) reported its financial results for Q2 2022, revealing a significant drop in revenue to $0, compared to $53,000 in Q2 2021. Despite achieving a gross profit of $20,488 last year, the company faced supply chain issues and regulatory challenges impacting sales. The net loss for Q2 2022 was $5 million, up from $1.4 million in Q2 2021. In positive developments, Atmofizer is expanding its HVAC market presence and has received a Notice of Allowance for new patent claims. The new customer lease-finance program aims to increase market access.

Atmofizer Technologies Inc. announced that independent testing of its Atmofizer ONE technology revealed a 99.99% effectiveness against targeted viruses and bacteria without filters. The test demonstrated over a 4-log reduction of microorganisms, including gram-positive and gram-negative bacteria and enveloped viruses. The FDA has not evaluated the technology, which operates under a policy for air purifiers amid the COVID-19 pandemic. Atmofizer aims to enhance air quality while reducing customer costs and environmental impact through its patented agglomeration technology.